Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070

British Journal of Cancer

Volumn 108, Issue 8, 2013, Pages 1634-1640

  O'Boyle, G ^a   Swidenbank, I ^a   Marshall, H ^a   Barker, C E ^a   Armstrong, J ^b   White, S A ^a   Fricker, S P ^c   Plummer, R ^a   Wright, M ^a   Lovat, P E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SUNDERLAND   (United Kingdom)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR;

ARTICLE; CELL MIGRATION; CELL VIABILITY; CHEMOTAXIS; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL;

AMINOQUINOLINES; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; CHEMOKINE CXCL12; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MELANOMA; RECEPTORS, CXCR4;

EID: 84877022870     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.124     Document Type: Article

References (26)

1. Armstrong JL, Corazzari M, Martin S, Pagliarini V, Falasca L, Hill DS, Ellis N, AL Sabah S, Redfern CP, Fimia GM, Piacentini M, Lovat PE (2011) Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res 17: 2216-2226.
2. Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16: 368-377.
3. Calandra G, Bridger G, Fricker SP (2010) CXCR4 in clinical hematology. Curr Top Microbiol Immunol 341: 173-191.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, Mcarthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
5. Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu, H (2012) BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 7: e42598.
6. Dale DC, Bolyard AA, Kelley ML, Westrup EC, Makaryan V, Aprikyan A, Wood B, Hsu FJ (2012) The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 118: 4963-4966.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
8. de Snoo FA, Hayward NK (2005) Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230: 153-186.
9. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 3883-3885.
10. Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, Losito S, La Mura A, Calemma R, Ierano C, Bryce J, D'Alterio C, Scala S (2010) CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Front Biosci (Elite Ed) 2: 13-21.
11. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445: 851-857.
12. Haughton EL, Tucker SJ, Marek CJ, Durward E, Leel V, Bascal Z, Monaghan T, Koruth M, Collie-Duguid E, Mann DA, Trim JE, Wright MC (2006) Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131: 194-209.
13. Hong F, Tuyama A, Lee TF, Loke J, Agarwal R, Cheng X, Garg A, Fiel MI, Schwartz M, Walewski J, Branch A, Schecter AD, Bansal MB (2009) Hepatic stellate cells express functional CXCR4: role in stromal cellderived factor-1alpha-mediated stellate cell activation. Hepatology 49: 2055-2067.
14. Knall C, Worthen GS, Buhl AM, Johnson GL (1995) IL-8 signal transduction in human neutrophils. Ann N Y Acad Sci 766: 288-291.
15. Kuhnelt-Leddihn L, Muller H, Eisendle K, Zelger B, Weinlich G (2012) Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10 Arch Dermatol Res 304: 185-193.
16. Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch-Machin MA, Redfern CP (2008) Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 68: 5363-5369.
17. Mellor P, Harvey JR, Murphy KJ, Pye D, O'Boyle G, Lennard TW, Kirby JA, Ali S (2007) Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer 97: 761-768.
18. Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, Lau G, Nelson K, Patel K, Santucci Z, Wong RSY, Skerlj RT, Bridger G, Huskens D, Schols D, Fricker SP (2012) The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol 83: 472-479.
19. Newton P, O'Boyle G, Jenkins Y, Ali S, Kirby JA (2009) T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol 47: 485-492.
20. O'Boyle G, Fox CR, Walden HR, Willet JD, Mavin ER, Hine DW, Palmer JM, Barker CE, Lamb CA, Ali S, Kirby JA (2012) Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc Natl Acad Sci USA 109: 4598-4603.
21. Schall TJ, Proudfoot AE (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11: 355-363.
22. Smalley KS (2010) PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Invest Drugs 11: 699-706.
23. Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, Macfarland RT, Park JG, Lalama C, Snyder S, Kallungal B, Klingman KL, Hendrix CW (2007) Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51: 2351-2358.
24. Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931.
25. Thompson JA (2012) Ten years of progress in melanoma. J Natl Compr Cancer Netw 10: 932-935.
26. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I (2006) Role of the CXCl12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 66: 2181-2187.